Biopsy Devices Market, By Product Outlook (Needle-based Biopsy Guns (Vacuum-assisted Biopsy Devices, Fine Needle Aspiration Biopsy Devices, Core Needle Biopsy devices), Guidance Systems (Manual, Robotic), Biopsy Needles (Non-Reusable, Reusable), Biopsy Forceps (General Forceps, Hot Forceps), Others (Brushes, Curettes, Punches)), By Region - Global Analysis Forecast Till 2030

The Biopsy Devices market size was valued at $3.5 Billion in 2022 and is expected to reach $4 Billion by 2030, registering a CAGR of 7.6% during the forecast period.

A biopsy is a surgical procedure that removes tissue from an organ to determine the presence or extent of the disease, most commonly cancerous and inflammatory conditions. It is performed by surgeons, radiologists, and interventional cardiologists. It can be performed on any organ using a specific biopsy device as a confirmatory test for cancer and celiac diseases. The application of each biopsy device differs depending on the type of organ under consideration. Conventional biopsy devices can be supplemented with advanced imaging technologies like MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others to perform a biopsy with accuracy and minimal invasiveness. Biopsies on organs such as the lungs, liver, and kidneys are performed using these integrated procedures.

Significant increases in cancer incidence, such as breast, prostate, and lung cancer, as well as rapid technological advancements like 3D optical biopsies, MRI-targeted biopsies, and Ultrasound-guided biopsies, drive the adoption of biopsy devices. Furthermore, increased awareness of chronic disease diagnosis fuels demands for integrated biopsy technologies such as stereotactic-guided biopsy. However, the high cost of biopsy devices and the need for more skilled professionals in low-income countries limit the Biopsy Devices market growth.

Market Dynamics

Drivers:

Rising patient awareness of cancer and advancements in biopsy techniques are also anticipated to temper market expansion. Furthermore, the Biopsy Devices market is predicted to benefit greatly from the increased research and development efforts in the field of biopsy instruments. The market for biopsy devices will continue to develop at a faster rate in the future because of the introduction of cutting-edge technologies like the Vacora and Finesse Ultra Breast Biopsy System and Celero VAB device.

Additionally, the need for less invasive biopsy treatments and the developing healthcare sector is anticipated to drive market expansion. Moreover, the Biopsy Devices market's expansion over the anticipated period is tempered by the surge in demand for less invasive biopsy techniques.

Restraints:

On the other hand, the strict regulation and criteria for the use of biopsy are anticipated to impede market expansion.

Additionally, the market's expansion is constrained by the high price of biopsy equipment. Factors including clinical problems with core needle biopsies and increased complaints about breast cancer screening procedures are expected to challenge the Biopsy Devices market.

Key players:

• Argon Medical Devices

• Becton, Dickinson and Company

• C.R. Bard, Inc., Hologic Inc

• Cardinal Health Inc.

• CONMED Corporation

• Cook Medical Incorporated

• Danaher Corporation

• Devicor Medical Products Inc.

• DTR Medical

• Encapsule Medical Devices LLC

• Ethicon Endo-Surgery (Johnson and Johnson)

• Gallini Srl

• Hologic, Inc.

• INRAD, Inc.

• Planmed OY

• TransMed7, LLC

Market Segmentation:

Biopsy Devices Market, By Product Outlook

• • Needle-based Biopsy Guns

    • Vacuum-assisted Biopsy (VAB) Devices

    • Fine Needle Aspiration Biopsy (FNAB) Devices

    • Core Needle Biopsy (CNB) devices

  • Biopsy Guidance Systems

    • Manual

    • Robotic

  • Biopsy Needles

    • Disposable

    • Reusable

  • Biopsy Forceps

    • General Biopsy Forceps

    • Hot Biopsy Forceps

  • Others

    • Brushes

    • Curettes

    • Punches 

Biopsy Devices Market, By Regional Outlook

• • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Regional Analysis:

In 2022, North America had a more than 40.0% revenue share. Due to established market players in the region, it will continue to account for a sizable market share throughout the forecast period. The indigenous request is anticipated to profit from high request penetration rates of technologically advanced bias similar as vacuum- supported vivisection systems and fleetly growing demand for disposable bias.

The number of biopsies done in the U.S. is the highest. According to a 2018 research study, "The Breast," 3 million breast biopsies are performed annually in the United States. Also, the U.S. FDA has a less strict nonsupervisory blessing process for medical bias since they're considered at moderate threat.  Several government health initiatives are in place to encourage people to get regular cancer screenings.

Asia Pacific offers numerous opportunities for market expansion. The rapid improvement of healthcare infrastructure in emerging Asia Pacific countries, the presence of high unmet patient needs, and the rising incidence of cancer are expected to drive regional market growth.

According to Global Cancer Statistics 2020, Asia is responsible for half of all cancer cases and cancer deaths. Similarly, reforms implemented in India and China is expected to increase healthcare establishments' purchasing power, thereby increasing assiduity growth.

Scope of the Report:

User

Tab Content